GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome

Federica Rachele Danti, Serena Galosi, Marta Romani, Martino Montomoli, Keren J Carss, F Lucy Raymond, Elena Parrini, Claudia Bianchini, Tony McShane, Russell C Dale, Shekeeb S Mohammad, Ubaid Shah, Neil Mahant, Joanne Ng, Amy McTague, Rajib Samanta, Gayatri Vadlamani, Enza Maria Valente, Vincenzo Leuzzi, Manju A KurianRenzo Guerrini

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: To describe better the motor phenotype, molecular genetic features, and clinical course ofGNAO1-related disease.

METHODS: We reviewed clinical information, video recordings, and neuroimaging of a newly identified cohort of 7 patients with de novo missense and splice siteGNAO1mutations, detected by next-generation sequencing techniques.

RESULTS: Patients first presented in early childhood (median age of presentation 10 months, range 0-48 months), with a wide range of clinical symptoms ranging from severe motor and cognitive impairment with marked choreoathetosis, self-injurious behavior, and epileptic encephalopathy to a milder phenotype, featuring moderate developmental delay associated with complex stereotypies, mainly facial dyskinesia and mild epilepsy. Hyperkinetic movements were often exacerbated by specific triggers, such as voluntary movement, intercurrent illnesses, emotion, and high ambient temperature, leading to hospital admissions. Most patients were resistant to drug intervention, although tetrabenazine was effective in partially controlling dyskinesia for 2/7 patients. Emergency deep brain stimulation (DBS) was life saving in 1 patient, resulting in immediate clinical benefit with complete cessation of violent hyperkinetic movements. Five patients had well-controlled epilepsy and 1 had drug-resistant seizures. Structural brain abnormalities, including mild cerebral atrophy and corpus callosum dysgenesis, were evident in 5 patients. One patient had a diffuse astrocytoma (WHO grade II), surgically removed at age 16.

CONCLUSIONS: Our findings support the causative role ofGNAO1mutations in an expanded spectrum of early-onset epilepsy and movement disorders, frequently exacerbated by specific triggers and at times associated with self-injurious behavior. Tetrabenazine and DBS were the most useful treatments for dyskinesia.

Original languageEnglish
Pages (from-to)e143
JournalNeurology. Genetics
Volume3
Issue number2
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome'. Together they form a unique fingerprint.

Cite this